About REGiMMUNE
REGiMMUNE is a company based in Tokyo (Japan) founded in 2006.. REGiMMUNE has raised $40.5 million across 10 funding rounds from investors including Sumitomo Mitsui Banking Corporation, Nippon Life Insurance and Icon Ventures. REGiMMUNE operates in a competitive market with competitors including GigaGen, Nuvalent, Enliven Therapeutics, Nura Bio and Actym Therapeutics, among others.
- Headquarter Tokyo, Japan
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$40.5 M (USD)
in 10 rounds
-
Latest Funding Round
$6 M (USD), Series E
Apr 07, 2017
-
Investors
Sumitomo Mitsui Banking Corporation
& 27 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of REGiMMUNE
REGiMMUNE has successfully raised a total of $40.5M across 10 strategic funding rounds. The most recent funding activity was a Series E round of $6 million completed in April 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Series E — $6.0M
-
First Round
First Round
(15 Aug 2006)
- Investors Count 28
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2017 | Amount | Series E - REGiMMUNE | Valuation | Japan Asia Investment , SMBC Venture Capital | |
| Feb, 2014 | Amount | Series D - REGiMMUNE | Valuation | Japan Asia Investment , Nippon Venture Capital | |
| Mar, 2012 | Amount | Series C - REGiMMUNE | Valuation | Chibagin Capital |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in REGiMMUNE
REGiMMUNE has secured backing from 28 investors, including venture fund and institutional investors. Prominent investors backing the company include Sumitomo Mitsui Banking Corporation, Nippon Life Insurance and Icon Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity platform is operated for investing in growth-oriented companies.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Investment support is provided to growing companies and sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by REGiMMUNE
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - REGiMMUNE
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Regimmune Comparisons
Competitors of REGiMMUNE
REGiMMUNE operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GigaGen, Nuvalent, Enliven Therapeutics, Nura Bio and Actym Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for cancer, including NSCLC inhibitors, are developed.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for solid tumours and blood cancers
|
|
| domain | founded_year | HQ Location |
Diagnostic solutions and neuroprotective medicines for neurological disorders are provided.
|
|
| domain | founded_year | HQ Location |
Immune therapy systems are developed for therapeutic applications.
|
|
| domain | founded_year | HQ Location |
RNA-modifying drug candidates are developed for multiple disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Regimmune
Frequently Asked Questions about REGiMMUNE
When was REGiMMUNE founded?
REGiMMUNE was founded in 2006.
Where is REGiMMUNE located?
REGiMMUNE is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Is REGiMMUNE a funded company?
REGiMMUNE is a funded company, having raised a total of $40.5M across 10 funding rounds to date. The company's 1st funding round was a Series C of $500K, raised on Aug 15, 2006.
What does REGiMMUNE do?
REGiMMUNE was founded in 2006 and is headquartered in Tokyo, Japan. Therapeutics for immune diseases are developed by the company through its proprietary reVax platform, which enables target-specific immunosuppression by inducing immune regulatory cells. A lead candidate, consisting of a liposomal formulation of alpha-GalCer, is currently in phase II trials for graft versus host disease. An additional candidate is under early-stage investigation for type I diabetes.
Who are the top competitors of REGiMMUNE?
REGiMMUNE's top competitors include GigaGen, Nuvalent and Enliven Therapeutics.
Who are REGiMMUNE's investors?
REGiMMUNE has 28 investors. Key investors include Sumitomo Mitsui Banking Corporation, Nippon Life Insurance, Icon Ventures, Resona Group, and Ministry of Economy, Trade and Industry.